<DOC>
	<DOC>NCT00484198</DOC>
	<brief_summary>This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator (Pioglitazone)-controlled, parallel-group study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period.</brief_summary>
	<brief_title>Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diagnosis of type 2 diabetes Male or female at least 18 years of age A1C &gt; 7% and less or equal to 8.5% Nonfasting Cpeptide &gt; 0.5ng/mL Current monotherapy treatment with stable dose of approved nonTZD antihyperglycemic medication for greater or equal to 3 months prior to screening or Untreated with any antihyperglycemic agent during 2 months prior to screening History of type 1 diabetes or ketoacidosis History of longterm therapy with insulin BMI &gt; 45 kg/m2 Known history of CHF Impaired hepatic function History of prior treatment failure with, or intolerance of, a TZD Contraindication to treatment with pioglitazone Treatment with fibrates If untreated with oral antihyperglycemic, considered to have failed diet and exercise modification as sole treatment for type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>